British Columbia's drug decriminalization policy was associated with a substantial decrease in police encounters for drug possession, while neither decriminalization nor the subsequent partial recriminalization was associated ...
3 hours ago
0
1
A new modeling study published in The Lancet suggests that U.S. Medicare's new "Most-Favored-Nation" pricing policy, which ties what Medicare pays for medicines to prices charged in other high-income countries, could push ...
8 hours ago
0
14
Over the past few decades, antibody-based therapies have revolutionized modern medicine and are now widely used to treat cancer, autoimmune diseases, inflammatory disorders and even infectious diseases. Despite their success, ...
10 hours ago
0
11
A new perspective from LSU's Pennington Biomedical Research Center proposes a new way of understanding how dietary protein restriction may promote healthy aging and extend lifespan: through a coordinated physiological response ...
15 hours ago
0
181
Researchers at the Icahn School of Medicine at Mount Sinai have found that small populations of pancreatic cancer cells can create localized immune-protective niches that shield tumors from immune attack. The finding could ...
13 hours ago
0
27
New results from the global phase 1/2 ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received ...
5 hours ago
0
4
Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients ...
5 hours ago
0
3
Researchers at Vanderbilt Health, UTHealth Houston and the University of North Carolina at Chapel Hill have identified early signs of cardiovascular-kidney-metabolic disease (CKMD) in children as young as 8 years old that ...
18 hours ago
0
13
An exploratory 8-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB–IIIA ...
5 hours ago
0
2
First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small ...
5 hours ago
0
1
